Conférence
mercredi 31 mars 2021

17h30

Young onset dementia: seven symptoms in search of a physiology

JD WARREN
Professor JD Warren, Professor of Neurology and Consultant Neurologist will give a conference about “Young onset dementia: seven symptoms in search of a physiology”.
Professor JD Warren

Professor JD Warren
Professor of Neurology and Consultant NeurologistUK Director, UCL MSc in Dementia (Neuroscience) Dementia Research Centre, UCL Queen Square Institute of Neurology University College London United Kingdom

Description
Young onset dementia poses unique challenges for the clinician. The comparative rarity and diversity of the culprit diseases make early detection difficult. This disease spectrum is often heralded by disturbances of socio-emotional behaviour, communication and other fragile functions for which we lack incisive diagnostic tools. Sensitive and reliable biomarkers are not available for most of the causative pathologies. Even when disease-modifying therapies become available, deploying treatment effectively in individual patients, caring for these patients and their families and meeting their often complex needs will remain significant problems for medicine and for society at large. In this talk I will consider seven cardinal (and sometimes puzzling) symptoms that illustrate major themes in young onset dementia. I will use these symptoms to argue that improved pathophysiological understanding and development of physiologically informed, dynamic disease markers are our best prospects for earlier and more accurate diagnosis and ultimately, bespoke treatment of young onset dementia.

Inscription : https://urlz.fr/ffy5

Replay de la conférence

Si vous n’êtes ni étudiant ni enseignant du MA2, le replay de la conférence est uniquement disponible en créant un compte MasterClass (gratuit) sur notre site web.

Autres conférences qui pourraient vous intéresser
jeudi 15 novembre 2018
Isabelle ARNULF
jeudi 13 janvier 2022
Gil RABINOVICI
Dans le cadre du cycle de conférences MA2, le Professeur Gil Rabinovici évoquera ses prises de position, pondérées et consensuelles, sur l'aducanumab.